Elite Pharmaceuticals Inc (ELTP) shareholders
Close on Oct 19, 2026Market cap $283.02MP/E 5.0Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ELTP | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Wall Street Access Asset Management, LLC | 1,000 | 0.00% | $365 | +500 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1 | 0M | 0.0% | 0 / 1 | 0 / 0 | 0M | 0M |
| Q1 2026 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q4 2025 | 1 | 0M | 0.0% | 0 / 0 | 0 / 1 | 0M | 0M |
| Q3 2025 | 2 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
| Q2 2025 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q1 2025 | 1 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
| Q4 2023 | 0 | 0M | 0.0% | 0 / 0 | 0 / 1 | 0M | 0M |
| Q3 2023 | 1 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
| Q2 2023 | 0 | 0M | 0.0% | 0 / 0 | 0 / 1 | 0M | 0M |
| Q1 2023 | 1 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
| Q4 2022 | 0 | 0M | 0.0% | 0 / 0 | 0 / 2 | 0M | 1M |
| Q3 2022 | 2 | 1M | 0.1% | 0 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Douglas Plassche | EVP Operations | 6,000,000 | 0.56% | Jan 13, 2026 |
| Pharmaceuticals Inc /Nv/ Elite | EVP Operations | 4,300,000 | 0.40% | Aug 26, 2025 |
| Kirko Kirkov | Chief Commercial Officer | 16,366 | 0.00% | Jul 25, 2025 |
| Aqeel Ahmad Fatmi | Director | – | – | Nov 9, 2026 |
| John LaRocca | Director | 88,534 | 0.01% | Nov 6, 2026 |
| Barry H. Dash | Director | 3,365,555 | 0.31% | Oct 19, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Barry H. Dash Director | Oct 9, 2026 | Buy | +100,000 | $0.26 | $25.98K | 3,365,555 |
| Barry H. Dash Director | Aug 19, 2026 | Buy | +30,000 | $0.29 | $8.70K | 3,265,555 |
| Douglas Plassche EVP Operations | Jan 9, 2026 | Option exercise | +2,500,000 | $0.03 | $75.00K | 6,000,000 |
| Douglas Plassche EVP Operations | Oct 2, 2025 | Sale | −800,000 | $0.62 | $496.00K | 3,500,000 |
| Pharmaceuticals Inc /Nv/ Elite EVP Operations | Aug 25, 2025 | Option exercise | +2,500,000 | $0.03 | $75.00K | 4,300,000 |
| Pharmaceuticals Inc /Nv/ Elite EVP Operations | Aug 22, 2025 | Sale | −500,000 | $0.52 | $260.00K | 1,800,000 |
| Kirko Kirkov Chief Commercial Officer | Jul 10, 2025 | Buy | +16,366 | $0.59 | $9.66K | 16,366 |
| Douglas Plassche EVP Operations | Jul 8, 2025 | Sale | −200,000 | $0.58 | $116.00K | 2,300,000 |
| Douglas Plassche EVP Operations | Jul 3, 2025 | Option exercise | +2,500,000 | $0.03 | $75.00K | 2,500,000 |
| Douglas Plassche SVP of Operations | Oct 24, 2024 | Sale | −333,932 | $0.51 | $170.31K | 0 |
| Douglas Plassche SVP of Operations | Oct 23, 2024 | Sale | −800,000 | $0.49 | $392.00K | 333,932 |
| Nasrat A. Hakim CEO, President, Director, 10% owner | Mar 29, 2024 | Award | +49,534,368 | – | – | 216,649,250 |
| Nasrat A. Hakim CEO, President, Director, 10% owner | Dec 29, 2023 | Award | +2,223,147 | $0.07 | $155.62K | 2,223,147 |
| Davis S. Caskey Director | Nov 22, 2023 | Award | +547,657 | $0.04 | $21.91K | 2,049,436 |
| Barry H. Dash Director | Nov 22, 2023 | Award | +547,657 | $0.04 | $21.91K | 3,235,555 |
| Jeffrey A. Whitnell Director | Nov 22, 2023 | Award | +547,657 | $0.04 | $21.91K | 3,187,020 |
| Barry H. Dash Director | Aug 28, 2022 | Award | +459,536 | $0.04 | $18.38K | 2,687,898 |
| Davis S. Caskey Director | Aug 28, 2022 | Award | +459,536 | $0.04 | $18.38K | 1,501,779 |
| Jeffrey A. Whitnell Director | Aug 28, 2022 | Award | +459,536 | $0.04 | $18.38K | 2,639,363 |
| Davis S. Caskey Director | Jun 30, 2021 | Award | +295,570 | $0.07 | $20.69K | 1,042,243 |
| Jeffrey A. Whitnell Director | Jun 30, 2021 | Award | +295,570 | $0.07 | $20.69K | 2,179,827 |
| Barry H. Dash Director | Jun 30, 2021 | Award | +295,570 | $0.07 | $20.69K | 2,228,182 |
| Nasrat A. Hakim CEO & President, Director, 10% owner | Aug 24, 2020 | Conversion | +158,017,321 | – | – | 167,114,882 |
| Barry H. Dash Director | Aug 20, 2020 | Award | +516,781 | $0.09 | $46.51K | 1,932,612 |
| Jeffrey A. Whitnell Director | Aug 20, 2020 | Award | +516,781 | $0.09 | $46.51K | 1,884,257 |
| Davis S. Caskey Director | Aug 20, 2020 | Award | +516,781 | $0.09 | $46.51K | 746,673 |
| Douglas Plassche SVP Operations | Aug 20, 2020 | Award | +71,739 | $0.09 | $6.46K | 1,133,932 |
| Douglas Plassche SVP of Operations | Jun 30, 2020 | Award | +574,597 | $0.09 | $51.71K | 1,062,193 |
| Carter Julian Ward CFO, Sec., Treas. | Feb 26, 2018 | Award | +242,060 | $0.12 | $29.05K | 2,127,364 |
| Jeffrey A. Whitnell Director | Feb 26, 2018 | Award | +161,374 | $0.12 | $19.36K | 1,367,476 |
| Davis S. Caskey Director | Feb 26, 2018 | Award | +161,374 | $0.12 | $19.36K | 229,892 |
| Barry H. Dash Director | Feb 26, 2018 | Award | +161,374 | $0.12 | $19.36K | 1,415,831 |
| Eugene M. Pfeifer Director | Feb 26, 2018 | Award | +161,374 | $0.12 | $19.36K | 233,414 |
| Douglas Plassche SVP of Operations | Feb 26, 2018 | Award | +201,717 | $0.12 | $24.21K | 487,596 |
| Nasrat A. Hakim CEO & President, Director, 10% owner | Apr 28, 2017 | Other | −158,017,321 | – | – | 9,097,561 |
| Davis S. Caskey Director | Feb 23, 2017 | Award | +68,518 | $0.20 | $13.70K | 68,518 |
| Nasrat A. Hakim CEO & President, Director, 10% owner | Feb 23, 2017 | Award | +2,216,992 | $0.23 | $509.91K | 24,143,785 |
| Jeffrey A. Whitnell Director | Feb 23, 2017 | Award | +88,679 | $0.23 | $20.40K | 1,206,102 |
| Carter Julian Ward Director | Feb 23, 2017 | Award | +133,019 | $0.23 | $30.59K | 1,885,304 |
| Barry H. Dash Director | Feb 23, 2017 | Award | +88,679 | $0.23 | $20.40K | 1,254,457 |
| Eugene M. Pfeifer Director | Feb 23, 2017 | Award | +72,040 | $0.20 | $14.41K | 72,040 |
| Douglas Plassche SVP of Operations | Feb 23, 2017 | Award | +110,849 | $0.23 | $25.50K | 285,879 |
| Nasrat A. Hakim CEO & President, Director, 10% owner | Aug 17, 2016 | Option exercise | +142,857,143 | – | – | 142,971,097 |
| Carter Julian Ward CFO, Secretary, Treasurer | Apr 28, 2016 | Conversion | +666,667 | $0.06 | $40.00K | 1,752,285 |
| Jeenarine Narine – | Apr 13, 2016 | Conversion | +4,000,000 | $0.06 | $240.00K | 16,742,395 |
| Jerry Treppel – | Mar 18, 2016 | Sale | −258,090 | $0.34 | $87.75K | 7,640,561 |
| Jerry Treppel – | Mar 17, 2016 | Sale | −312,430 | $0.35 | $109.35K | 7,898,651 |
| Jerry Treppel – | Feb 24, 2016 | Sale | −100,456 | $0.31 | $31.14K | 8,211,081 |
| Jerry Treppel – | Feb 22, 2016 | Sale | −100,000 | $0.32 | $32.00K | 8,311,537 |
| Jerry Treppel – | Feb 17, 2016 | Sale | −50,000 | $0.31 | $15.50K | 8,411,537 |
| Jeffrey A. Whitnell Director | Feb 16, 2016 | Award | +81,549 | $0.25 | $20.39K | 1,117,423 |
| Carter Julian Ward CFO, Sec., Treas | Feb 16, 2016 | Award | +122,325 | $0.25 | $30.58K | 1,085,618 |
| Nasrat A. Hakim Chairman, CEO, President, Director, 10% owner | Feb 16, 2016 | Award | +2,854,279 | $0.25 | $713.57K | 22,040,747 |
| Jerry Treppel – | Feb 16, 2016 | Award | +124,646 | $0.25 | $31.16K | 8,461,537 |
| Barry H. Dash Director | Feb 16, 2016 | Award | +81,549 | $0.25 | $20.39K | 1,165,778 |
| Jeenarine Narine Director | Feb 16, 2016 | Award | +81,549 | $0.25 | $20.39K | 12,742,395 |
| Douglas Plassche Exec Vice Pres Operations | Feb 16, 2016 | Award | +47,767 | $0.26 | $12.42K | 175,030 |
| Jerry Treppel – | Feb 5, 2016 | Sale | −24,400 | $0.33 | $8.05K | 8,336,891 |
| Jerry Treppel – | Feb 4, 2016 | Sale | −349,660 | $0.32 | $111.89K | 8,361,291 |
| Jerry Treppel – | Feb 3, 2016 | Sale | −45,518 | $0.33 | $15.02K | 8,710,951 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Elite Pharmaceuticals's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Douglas Plassche Officer | Aug 22, 2025 | 100,000 | $555.00K | Aug 22, 2025 | Stock Options Exercise |
| Douglas Plassche Officer | Jul 8, 2025 | 500,000 | $303.00K | Jul 8, 2025 | Stock Options Exercise |
| Douglas Plassche Officer | Oct 23, 2024 | 1,133,932 | $680.36K | Oct 23, 2024 | Payment for Services Rendered |
See a number that looks wrong?